0001209191-23-002054.txt : 20230105
0001209191-23-002054.hdr.sgml : 20230105
20230105182111
ACCESSION NUMBER: 0001209191-23-002054
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230103
FILED AS OF DATE: 20230105
DATE AS OF CHANGE: 20230105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SHERWIN STEPHEN A
CENTRAL INDEX KEY: 0001079462
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 23512864
MAIL ADDRESS:
STREET 1: C/O CELL GENESYS, INC.
STREET 2: 500 FORBES BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-03
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001079462
SHERWIN STEPHEN A
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
1
0
0
0
Common Stock
2023-01-03
4
M
0
15000
12.71
A
40055
D
Common Stock
2023-01-03
4
S
0
15000
118.8651
D
25055
D
Common Stock
2023-01-03
4
M
0
15000
12.98
A
40055
D
Common Stock
2023-01-03
4
S
0
15000
118.8501
D
25055
D
Non-Qualified Stock Option
12.71
2023-01-03
4
M
0
15000
12.71
D
2023-05-23
Common Stock
15000
0
D
Non-Qualified Stock Option
12.98
2023-01-03
4
M
0
15000
12.98
D
2024-05-22
Common Stock
15000
0
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $117.75 to $119.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Option granted May 23, 2013 and vested monthly over one year.
Option granted May 22, 2014 and vested monthly over one year.
/s/ Darin Lippoldt, Attorney-in-Fact
2023-01-05